Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy.
NLR
bladder
bladder cancer
neutrophil-to-lymphocyte ratio
prognostic
radical cystectomy
urothelial carcinoma
Journal
Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
03
2023
revised:
19
04
2023
accepted:
29
04
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
The pre-treatment neutrophil-to-lymphocyte ratio (NLR) has been associated with adverse pathology or survival in a variety of malignancies, including urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). Whether the prognostic value of NLR is retained, or even increased, when measured postoperatively remains to be studied. In this study, we evaluated the association of preoperative and postoperative NLR with oncological outcomes following RC. The NLR was recorded in 132 consecutive patients with UCB treated with open RC: before surgery (NLR1), postoperatively within 2 days (NRL2), between 7 and 15 days after RC before discharge (NLR3), and a few days before recurrence or last available follow-up (NLR4). When assessed by multivariate analysis NLR1 remained independently associated with a significantly increased risk of extravesical disease (pT 3-4) (OR = 1.4, p <0.01) and lymphovascular invasion (LVI) (OR = 1.40, 95% CI 1.09-1.83, p <0.01). NLR4 was independently associated with a significantly increased risk of cancer-specific mortality (CSM) (HR = 1.14, 95%CI 1.03-1.24, p = 0.013). In a postoperative model, NLR3 was found to be an independent predictor of all-cause mortality (ACM) [HR = 1.11, 95% CI 1.02-1.21, p = 0.01]. NLR1 was associated with a significantly increased risk of recurrence in the univariable preoperative model [HR = 1.9, 95%CI 1.00-3.65, p = 0.05], while in the postoperative model NLR4 remained independently associated with a significantly increased risk of recurrence (HR = 1.13, 95%CI 1.04-1.23, p = 0.03). In patients with UCB treated with RC, the NLR is associated with more advanced tumour stage, LVI, lymph node metastasis, and higher CSM. Furthermore, the variation of the NLR after surgery might play a role in predicting higher ACM and recurrence-free survival.
Identifiants
pubmed: 37483852
doi: 10.5173/ceju.2023.039
pii: 39
pmc: PMC10357830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90-103Informations de copyright
Copyright by Polish Urological Association.
Déclaration de conflit d'intérêts
Øyvind Ulvik has acted as a consultant for Olympus. The other authors have nothing to declare.
Références
Pharmacoeconomics. 2003;21(18):1315-30
pubmed: 14750899
Oncologist. 2015 May;20(5):508-15
pubmed: 25845990
Tumour Biol. 2014 Jul;35(7):6601-5
pubmed: 24696263
Cent European J Urol. 2022;75(1):41-46
pubmed: 35591971
Future Sci OA. 2021 Apr 20;7(7):FSO709
pubmed: 34258022
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Future Oncol. 2021 Oct;17(30):3987-3994
pubmed: 34278815
Jpn J Clin Oncol. 2015 Dec;45(12):1162-7
pubmed: 26423342
Eur Urol. 2014 Dec;66(6):1157-64
pubmed: 24630414
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Oncology. 2007;73(3-4):215-20
pubmed: 18424885
J Urol. 2010 Sep;184(3):873-8
pubmed: 20643463
Urology. 2012 May;79(5):1085-91
pubmed: 22446338
J Urol. 2010 Jun;183(6):2165-70
pubmed: 20399473
Korean J Urol. 2015 Nov;56(11):749-55
pubmed: 26568792
PLoS One. 2014 May 02;9(5):e96072
pubmed: 24788770
Biochemistry (Mosc). 2016 Feb;81(2):80-90
pubmed: 27260388
J Endourol. 2013 Aug;27(8):1046-50
pubmed: 23517015
Eur Urol Focus. 2016 Apr;2(1):79-85
pubmed: 28723455
Cancer Immunol Immunother. 2009 Jan;58(1):15-23
pubmed: 18414853
BJU Int. 2010 May;105(10):1402-12
pubmed: 20132195
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Urol Oncol. 2014 Jul;32(5):631-6
pubmed: 24629498
Br J Cancer. 2016 Jan 19;114(2):207-12
pubmed: 26657651
Front Oncol. 2023 Mar 29;13:1114203
pubmed: 37064102
Ann Surg Oncol. 2016 Jan;23(1):335-42
pubmed: 26152275
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E126-31
pubmed: 25844098
Urol Oncol. 2015 Feb;33(2):67.e1-7
pubmed: 25060672
Ann Surg Oncol. 2012 Jan;19(1):217-24
pubmed: 21638095
Br J Cancer. 2013 Jul 23;109(2):401-7
pubmed: 23820256
Tumour Biol. 2015 Nov;36(11):8537-43
pubmed: 26032095
Br J Cancer. 2014 Jul 29;111(3):444-51
pubmed: 24918819
Urol Int. 2012;89(4):468-72
pubmed: 23128367
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Urology. 2017 Oct;108:122-128
pubmed: 28739405
Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E789-94
pubmed: 26600886